Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
Moderna(MRNA) stock is priced at $144.48, giving the company a market capitalization of 59.75B. It carries a P/E multiple of -18.74.
During the trading session on 2026-08-27, Moderna(MRNA) shares reached a daily high of $158.43 and a low of $145.11. At a current price of $144.48, the stock is -0.4% higher than the low and still -8.8% under the high.
Trading volume for Moderna(MRNA) stock has reached 22.01M, versus its average volume of 51M.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $176.66 and a low of $22.28.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $176.66 and a low of $22.28.
MRNA News
Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips By David Moadel Published Aug 26, 11:25AM EDT Quick Read Moderna shed 7% of Tuesday's...
Shares of Moderna Inc. (NASDAQ:MRNA) are trading slightly lower Wednesday morning, taking a brief pause after surging more than 150% following landmark clinical...
In August 2026, Merck & Co. and Moderna reported positive Phase 3 results from the INTerpath-001 trial, showing that individualized mRNA neoantigen therapy inti...
Analyst ratings
69%
of 26 ratingsMore MRNA News
Moderna (MRNA) is up 13.0%, or $18.02 to $156.91. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now...
Biotech firm Moderna (MRNA) saw its stock rise 12.5% today, building on a multi-day rally after releasing positive Phase 3 trial data for its personalized mRNA...
Wolfe Research upgraded Moderna (MRNA) to Peer Perform from Underperform without a price target The firm says the positive melanoma trial de-risks the intismera...
Moderna stock has surged over the past year, yet the company currently screens as expensive on Simply Wall St's broader valuation checks. This raises questions...
Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze By Thomas Richmond Updated Aug 24, 6:17PM EDT · Published Aug 24, 8:59AM EDT Quick...
Barclays analyst Eliana Merle raised the firm’s price target on Moderna (MRNA) to $125 from $48 and keeps an Equal Weight rating on the shares. The stock at cur...
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. Fo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.